AbClon Inc.
Financials
Valuation Metrics
AbClon Inc.'s Market Cap is ₩3877B. At end of 2025 it was ₩8480B. Ranked #552 of 2,421 in KR market (top 23%), #217 of 1,640 on KOSDAQ (top 13%), #59 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 387.67B KRW | KR#552/2,421 Sec#59/231 |
| Revenue | 5.31B KRW | KR#2,337/2,421 Sec#194/231 |
| Net Income | -17.30B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 64.50B KRW | KR#2,062/2,421 Sec#176/231 |
| Net Assets | 53.07B KRW | KR#1,868/2,421 Sec#159/231 |
| Employees | 63 | KR#1,940/2,421 Sec#171/231 |
| Value | ||
| P/B | 7.30x | KR#2,315/2,421 Sec#202/231 |
| P/S | 73.04x | KR#2,382/2,421 Sec#202/231 |
| FCF Yield | -3.72% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -32.60% | KR#2,203/2,421 Sec#183/231 |
| ROA | -26.82% | KR#2,295/2,421 Sec#194/231 |
| Op. Margin | -336.22% | KR#2,352/2,421 Sec#196/231 |
| Revenue Growth | 75.02% | KR#127/2,421 Sec#20/231 |
| Financial Health | ||
| Debt Ratio | 21.54% | KR#405/2,421 Sec#49/231 |
| Total Debt | 7.00B KRW | KR#1,722/2,421 Sec#159/231 |
| FCF | -14.42B KRW | KR#1,809/2,421 Sec#166/231 |
| Cash | 30.38B KRW | KR#1,003/2,421 Sec#68/231 |
| Current Ratio | 3.89x | KR#404/2,421 Sec#63/231 |
| Performance | ||
| 1Y Return | 45.65% | KR#284/2,421 Sec#16/231 |
| 1M Return | -34.69% | KR#2,367/2,421 Sec#225/231 |
| From 52W High | -79.72% | KR#2,340/2,421 Sec#217/231 |
| 1Y MDD | -81.12% | KR#2,316/2,421 Sec#214/231 |
| Trading | ||
| Volume | 110,653 shares | KR#735/2,421 Sec#67/231 |
| Trading Value | 2.16B KRW | KR#543/2,421 Sec#51/231 |
| Foreign Own. | 7.73% | KR#574/2,421 Sec#47/231 |
| Per Share | ||
| EPS | -867 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,660 KRW | KR#1,927/2,421 Sec#150/231 |
Company Info
AbClon, established in 2010 and headquartered in Guro-gu, Seoul, is a bio-venture focused on antibody new drug development, manufacturing, and sales, specially listed on KOSDAQ in 2017. The company utilizes platforms such as NEST, AffiMab, and CAR-T, maintaining a research network with Atlas in Sweden. AbClon licensed AC101, developed with NEST technology, to Shanghai Henlius, and its CAR-T therapeutic AT101 is currently in Phase 2 clinical trials. It aims to strengthen its immune cell therapy presence through a partnership with Chong Kun Dang in 2025.